Edwards gets Japanese nod for stentless heart valve:
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences has gained approval to take its Prima Plus stentless porcine tissue heart valve to the Japanese market. The device has been available in Europe since 1998 and in the US since 2001. The Irvine, California firm said it expected to obtain reimbursement approval from the country's Ministry of Health, Labour and Welfare (MHLW) within the next few weeks, and to begin sales immediately thereafter.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.